Idelvion (Albutrepenonacog Alfa)

Albutrepenonacog Alfa is a fusion protein that combines factor VIII with an IgG Fc fragment, extending its circulation time. After intravenous infusion, it restores factor VIII activity in the intrinsic coagulation pathway, enabling the formation of a stable fibrin clot and reducing bleeding risk.

The dose of Idelvion is individualized by the prescribing clinician based on the patient’s weight, severity of hemophilia, type of bleed, and prophylactic needs. Dosing regimens are determined by a qualified healthcare professional and are not standardized across all patients.

Safety data for Idelvion in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and treatment decisions should be made in consultation with a specialist obstetrician‑haematologist.

To order Idelvion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Idelvion’s Fc‑fusion design gives it a longer plasma half‑life than standard factor VIII concentrates, allowing less frequent dosing for prophylaxis. While efficacy is comparable, the extended dosing interval can improve adherence, though individual response and inhibitor risk must be evaluated for each patient.

Idelvion must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for discoloration before use.

Idelvion is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescriber, and the product should be diluted according to the manufacturer’s instructions before administration.

The most serious risks include the development of neutralising factor VIII inhibitors, severe allergic reactions such as anaphylaxis, and rare thromboembolic events. Patients should be monitored closely for signs of these reactions, especially during the initial treatment period.

Idelvion is contraindicated in patients with a known hypersensitivity to Albutrepenonacog Alfa or any of its excipients. Individuals with a history of severe allergic reactions to factor VIII products should avoid its use, and clinicians should assess each patient’s risk before initiating therapy.